Hydra Biosciences

company

About

Hydra Biosciences develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using ion channels.

  • 1 - 10

Details

Last Funding Type
Series A
Last Funding Money Raised
$9.30M
Industries
Biotechnology,Life Science,Medical
Founded date
Jan 1, 2001
Number Of Employee
1 - 10
Operating Status
Active

Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs.

Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs.

Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$28.17M
Hydra Biosciences has raised a total of $28.17M in funding over 2 rounds. Their latest funding was raised on Jan 12, 2004 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 12, 2004 Series B $18.87M 1 Detail
Jul 26, 2002 Series A $9.30M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Hydra Biosciences is funded by 1 investors. Boston Medical Investors are the most recent investors.
Investor Name Lead Investor Funding Round
Boston Medical Investors Series B